Company Of The Day: Johnson & Johnson
What?
Johnson & Johnson (NYSE:J&J) plans to split into two publically traded companies. The first company will hold the company’s prescription-drug and medical-device businesses. The second will hold the company’s consumer businesses.
So What?
Relevant Articles
- Should You Buy Johnson & Johnson Stock At $177?
- Here’s Why Centene Stock Is A Better Bet Compared To This Pharmaceuticals Bellwether
- This Semiconductor Chip Company Is Likely To Offer Better Returns Over Johnson & Johnson Stock
- Does Johnson & Johnson Stock Have More Upside?
- Company Of The Day: Johnson & Johnson
- Here’s Why Humira Maker Is A Better Bet Compared To Johnson & Johnson Stock
While J&J’s consumer business is very high profile, it lags the pharma business in terms of growth and profitability. With the planned split, J&J could potentially unlock some value for shareholders.
See Our Complete Analysis For Johnson & Johnson
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates